A Recall Notice with Unusually Specific Risk Language
Most drug recall notices are written in careful, hedged language. This one is not.
American Regent has recalled a single lot of papaverine hydrochloride injection nationwide after finding visible particulate matter in the product, identified as glass and paraformaldehyde. In its recall announcement, the company stated that particulate matter "could travel through and block blood vessels in the heart, lungs or brain," which it said can cause stroke and may lead to death. Patients with existing cardiovascular or pulmonary conditions may face higher risk.
The company said it has received no reports of adverse events connected to this lot.
The recall is narrow in scope. It covers one lot of papaverine hydrochloride injection, USP, 60 mg per 2 mL, in single-dose vials, lot number 25202, NDC 0517-4002-25, with an expiration date of November 30, 2026. The lot was distributed nationwide beginning in late September of last year.
Why Particles in an Injectable Are a Different Category of Problem
This is the part worth understanding, because it explains why a single lot recall carries language this serious.
Most drug recalls involve a product that is the right substance in the wrong condition. Tablets that do not dissolve properly, a label with an incorrect expiration date, a batch that is slightly under potency. In those cases, the failure mode is that the medicine works less well than intended, and the harm is usually gradual and reversible.
Particulate matter in an injectable is different because the delivery route removes every natural filter. A tablet passes through the stomach and intestine. An intravenous injection goes straight into the bloodstream. Solid particles introduced there travel with the blood until they reach a vessel narrower than they are, and then they stop. Where they stop determines what happens. In the lungs, that can produce a pulmonary embolism. In the brain, it can produce a stroke. The most common consequence is far milder, local irritation or swelling at the injection site, but the range of possible outcomes extends much further than for an oral product.
This is why regulators treat visible particulates in sterile injectables as a distinct and higher tier of manufacturing failure, and why companies typically recall the entire lot rather than attempting to sort good vials from bad. It is also why these recalls reach the hospital and clinic level rather than the pharmacy shelf.
The problem is not rare. In May, Sun Pharma recalled a single batch of 675 vials of a liposomal doxorubicin chemotherapy injection after glass particles were found in some vials during production. That company's notice to the FDA warned of "blockage of blood vessels and life-threatening blood clot events." Glass particulate recalls have also involved sodium bicarbonate and lidocaine injectables in recent years.
Who Actually Received This Drug
Papaverine is not a household medication, and identifying the affected group is more useful than a general alert.
It is a prescription smooth muscle relaxant that widens blood vessels. Clinically, it is used for visceral spasm, for poor circulation, and in urology for erectile dysfunction, where it is sometimes given by injection. It is administered by or under the direction of a physician rather than picked up at a retail pharmacy counter.
That means the people who received this lot encountered it in a hospital, surgical center, urology practice, or interventional radiology suite. Most patients would have no way of knowing the lot number of a drug administered to them, and there is no consumer packaging to check at home.
The exception is patients who were prescribed vials to self-administer at home, which does occur in some urology practice patterns. Those patients can check the vial label directly for lot 25202.
The lot was distributed starting in late September of last year, and its expiration date falls in November of this year. That gap matters in both directions. A supply distributed ten months ago has largely been used, which limits exposure going forward. It also means any patient who received a dose from this lot would have done so months ago, and the company reports no adverse events across that period.
What Patients and Providers Should Do
Facilities holding the recalled lot should stop using it immediately and return it to the place of purchase or discard it, according to the company. American Regent is notifying distributors and customers by letter and arranging returns and replacements.
Patients who have vials at home should stop using them and contact the prescribing clinician for a replacement rather than simply discontinuing treatment. Do not stop a prescribed medication without speaking to a health care professional.
Anyone who received papaverine injection since last autumn and has since experienced unexplained chest pain, sudden shortness of breath, sudden weakness or numbness on one side of the body, difficulty speaking, or sudden vision changes should seek urgent medical evaluation and mention the recall. Those are symptoms of vessel blockage, and they warrant emergency assessment regardless of cause. Milder local reactions such as pain, swelling, or redness at an injection site should be reported to the prescribing clinician.
There is no reason for anyone who did not receive this specific product to take action. Patients using other injectable medications are not affected by this recall.
Adverse reactions or quality problems can be reported to the FDA's MedWatch program online or by calling 1-800-332-1088. American Regent's pharmacovigilance line is 1-800-734-9236.
What Happens Next
The FDA has not yet published a classification for this recall. Classification indicates the agency's assessment of the probability of serious harm, and it typically follows a company announcement by several weeks. That determination will appear in the agency's enforcement report and is the next meaningful development to watch.
Recalls of this type are occasionally expanded if an investigation identifies additional affected lots. The company has described this as a precautionary action and said it is committed to patient safety, and has not indicated that other lots are implicated. American Regent has not published the root cause of the contamination.
The confirmed facts are that one lot of papaverine hydrochloride injection has been recalled nationwide for glass and paraformaldehyde particles, that the manufacturer's stated risk includes vessel blockage and stroke, and that no adverse events have been reported. The people affected are the limited number of patients who received this specific lot, mostly in clinical settings. The most reasonable action for the general public is none, and for anyone holding a vial it is to check lot 25202 and contact a clinician. The central uncertainty is the FDA's classification and whether the investigation reaches additional lots.
Frequently Asked Questions
What exactly was recalled? One lot of papaverine hydrochloride injection, USP, 60 mg per 2 mL single-dose vials, lot 25202, NDC 0517-4002-25, expiring November 30, 2026. It was distributed nationwide starting in late September of last year.
What is papaverine used for? It is a prescription smooth muscle relaxant that widens blood vessels, used for visceral spasm, poor circulation, and erectile dysfunction. It is given by injection under a physician's direction.
Why are particles in an injectable more serious than in a pill? An injection bypasses the digestive tract and enters the bloodstream directly. Solid particles can travel until they lodge in a vessel too narrow to pass, potentially blocking blood flow in the lungs, heart, or brain.
Has anyone been harmed? The company reports no adverse events related to this recall as of its announcement.
How do I know if I received the recalled lot? Most patients received this drug in a clinical setting and would not have the lot number. Contact the facility where you were treated. Patients with vials at home can check the label for lot 25202.
What symptoms should prompt urgent care? Chest pain, sudden shortness of breath, sudden one-sided weakness or numbness, difficulty speaking, or sudden vision changes require emergency evaluation.
Should I stop my treatment? Do not stop a prescribed medication on your own. Contact the prescribing clinician about a replacement.
